Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Phase 3

Completed

• Conditions: Moderate-to-Severe Atopic Dermatitis
• Interventions: Drug: Placebo; Drug: Nemolizumab

• Registration Number: NCT03989349
• Lead Sponsor: Galderma R&D

Brief Summary

The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

Detailed Description

This was a randomized, double-blind, placebo-controlled, multi-center, parallel-group study in adult and adolescent subjects of age 12 years and above with moderate-to-severe AD. Eligible subjects had documented history of inadequate response to topical AD medication(s). Approximately 750 subjects were randomized in 2:1 to receive either nemolizumab or placebo, stratified by baseline disease severity (Investigator's Global Assessment (IGA) = 3, moderate; IGA = 4, severe) and peak pruritus numeric rating scale (PP NRS) severity (PP NRS \>= 7; PP NRS \< 7). A minimum of 250 subjects were randomized in each PP NRS strata. All nemolizumab-treated subjects who were clinical responders at Week 16 (i.e., the end of initial treatment \[Initial Treatment Period\]/beginning of Maintenance Period) were re-randomized (1:1:1) to different treatment regimens (nemolizumab injections Q4W or every 8 weeks (Q8W) \[with placebo injections at Weeks 20, 28, 36, and 44 to maintain the blind\] or placebo Q4W). A clinical responder was defined as a subject at Week 16 with an IGA of 0 (clear) or 1 (almost clear) or a \>=75% improvement in EASI from baseline (EASI-75). All placebo-treated subjects who responded to placebo during the Initial Treatment Period continued to receive placebo Q4W in the Maintenance Period.

Study Timeline

• Study First Submitted: 2019-06-14
• Study First Submitted QC: 2019-06-14
• Study First Posted: 2019-06-18
• Study Start: 2019-06-30
• Primary Completion: 2022-02-23
• Study Completion: 2022-09-26
• Disposition First Submitted: 2023-09-19
• Results First Submitted: 2024-06-21
• Status Verified: 2024-08
• Results First Submitted QC: 2024-08-09
• Last Update Submitted: 2024-08-09
• Results First Posted: 2024-08-14
• Disposition First Posted: 2024-08-14
• Last Update Posted: 2024-08-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 787

Inclusion Criteria

• Male or female subjects aged greater than and equal to (>=) 12 years at the screening visit.
• Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for at least 2 years before the screening visit.
• Eczema Area and Severity Index (EASI) score >=16 at the screening and baseline visits.
• Investigator Global Assessment (IGA) score >= 3 (scale of 0 to 4) at the screening and baseline visits.
• AD involvement >= 10 percent (%) of body surface area (BSA) at screening and baseline visits.
• Peak Pruritus Numerical Rating Scale (PPNRS) score of at least 4.0 at the screening and baseline visits.
• Documented recent history of inadequate response to topical medications (topical corticosteroids [TCS] with or without Topical calcineurin inhibitors [TCI]).
• Female subjects of childbearing potential (that is, fertile, following menarche and until becoming postmenopausal unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection.

Key

Read More

Exclusion Criteria

• Body weight (<) 30 kilograms (kg)
• Exacerbation of asthma requiring hospitalization in the preceding 12 months. Uncontrolled asthma in the preceding 3 months.
• Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 2 weeks before the baseline visit, or any confirmed or suspected coronavirus disease (COVID)-19 infection within 2 weeks before the screening or baseline visit.
• Pregnant women, breastfeeding women, or women planning a pregnancy during the clinical study.

Note: Subjects with chronic,stable use of prophylactic treatment for recurrent herpes viral infection can be included in this clinical study.

• History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody) or to any of the study drug excipients.
• Any clinically significant issue, based on investigator judgement.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo administered via subcutaneous injection
Nemolizumab	Nemolizumab	Nemolizumab administered via subcutaneous injection

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Severe Pruritus Population	Week 16	IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of AD and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered a treatment failure. Participants with missing data at Week 16 were considered non-responders.
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population	Week 16	EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD(erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered a treatment failure. Participants with missing data at Week 16 were considered non-responders.
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: Severe Pruritus Population	Week 16	EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD(erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered a treatment failure. Participants with missing data at Week 16 were considered non-responders.
Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population	Week 16	IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of atopic dermatitis (AD) and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population	Week 16	The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: ITT Population	Week 4	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population	Week 16	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population	Week 16	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population	Week 16	The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: Severe Pruritus Population	Week 1	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population	Week 16	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population	Week 16	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: Severe Pruritus Population	Week 4	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: ITT Population	Week 4	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: Severe Pruritus Population	Week 4	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: ITT Population	Week 2	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: Severe Pruritus Population	Week 2	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: ITT Population	Week 1	The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Trial Locations

Locations (138)

Galderma Investigational Site 8721; 🇺🇸 Pittsburgh, Pennsylvania, United States

Galderma Investigational Site 8807; 🇺🇸 Houston, Texas, United States

Galderma Investigational Site 8719; 🇺🇸 Miami, Florida, United States

Galderma Investigational Site 8704; 🇺🇸 Miami, Florida, United States

Galderma Investigational Site 8672; 🇺🇸 Salt Lake City, Utah, United States

Galderma Investigational Site 8749; 🇺🇸 Birmingham, Alabama, United States

Galderma Investigational Site 8212; 🇺🇸 Portland, Oregon, United States

Galderma Investigational Site 8893; 🇺🇸 Birmingham, Alabama, United States

Galderma Investigational Site 8866; 🇺🇸 Guntersville, Alabama, United States

Galderma Investigational Site 8906; 🇺🇸 Bell Gardens, California, United States

Galderma Investigational Site 8905; 🇺🇸 Canoga Park, California, United States

Galderma Investigational Site 8808; 🇺🇸 Scottsdale, Arizona, United States

Galderma Investigational Site 8683; 🇺🇸 Los Angeles, California, United States

Galderma Investigational Site 8673; 🇺🇸 Garden Grove, California, United States

Galderma Investigational Site 8907; 🇺🇸 Newport Beach, California, United States

Galderma Investigational Site 8799; 🇺🇸 Ontario, California, United States

Galderma Investigational Site 8658; 🇺🇸 San Diego, California, United States

Galderma Investigational Site 8745; 🇺🇸 Pasadena, California, United States

Galderma Investigational Site 8536; 🇺🇸 Santa Ana, California, United States

Galderma Investigational Site 8727; 🇺🇸 Hialeah, Florida, United States

Galderma Investigational Site 8523; 🇺🇸 Largo, Florida, United States

Galderma Investigational Site 8656; 🇺🇸 Miami, Florida, United States

Galderma Investigational Site 8825; 🇺🇸 Las Vegas, Nevada, United States

Galderma Investigational Site 8747; 🇺🇸 Cincinnati, Ohio, United States

Galderma Investigational Site 8823; 🇺🇸 Greensboro, North Carolina, United States

Galderma Investigational Site 8705; 🇺🇸 Chattanooga, Tennessee, United States

Galderma Investigational Site 8618; 🇺🇸 Waco, Texas, United States

Galderma Investigational Site 5448; 🇧🇪 Brussel, Belgium

Galderma Investigational Site 6164; 🇧🇪 Gent, Belgium

Galderma Investigational Site 6162; 🇧🇪 Liège, Belgium

Galderma Investigational Site 6038; 🇧🇪 Leuven, Belgium

Galderma Investigational Site 6165; 🇧🇬 Sofia, Bulgaria

Galderma Investigational Site 6250; 🇧🇬 Sofia, Bulgaria

Galderma Investigational Site 6170; 🇫🇷 Martigues, France

Galderma Investigational Site 5140; 🇫🇷 Nice, France

Galderma Investigational Site 6133; 🇫🇷 Paris, France

Galderma Investigational Site 6169; 🇫🇷 Toulouse, France

Galderma Investigational Site 6135; 🇫🇷 Quimper, France

Galderma Investigational Site 6197; 🇫🇷 Toulon, France

Galderma Investigational Site 6227; 🇬🇪 Tbilisi, Georgia

Galderma Investigational Site 6224; 🇬🇪 Tbilisi, Georgia

Galderma Investigational Site 6031; 🇩🇪 Duesseldorf, Germany

Galderma Investigational Site 5442; 🇩🇪 Gera, Germany

Galderma Investigational Site 6040; 🇩🇪 Hamburg, Germany

Galderma Investigational Site 6084; 🇩🇪 Mainz, Germany

Galderma Investigational Site 6086; 🇩🇪 Kiel, Germany

Galderma Investigational Site 6254; 🇭🇺 Gyula, Hungary

Galderma Investigational Site 6141; 🇮🇹 Chieti, Italy

Galderma Investigational Site 6045; 🇮🇹 L'Aquila, Italy

Galderma Investigational Site 6151; 🇮🇹 Parma, Italy

Galderma Investigational Site 6180; 🇮🇹 Pavia, Italy

Galderma Investigational Site 6044; 🇮🇹 Roma, Italy

Galderma Investigational Site 6177; 🇮🇹 Rome, Italy

Galderma Investigational Site 6049; 🇮🇹 Roma, Italy

Galderma Investigational Site 5773; 🇵🇱 Białystok, Poland

Galderma Investigational Site 6052; 🇵🇱 Kraków, Poland

Galderma Investigational Site 6185; 🇵🇱 Wrocław, Poland

Galderma Investigational Site 5363; 🇵🇱 Łódź, Poland

Galderma Investigational Site 8203; 🇺🇸 Tampa, Florida, United States

Galderma Investigational Site 8839; 🇺🇸 Tampa, Florida, United States

Galderma Investigational Site 8577; 🇺🇸 Encinitas, California, United States

Galderma Investigational Site 8637; 🇺🇸 Farmington, Connecticut, United States

Galderma Investigational Site 8875; 🇺🇸 Delray Beach, Florida, United States

Galderma Investigational Site 8820; 🇺🇸 Westminster, California, United States

Galderma Investigational Site 8391; 🇺🇸 Hialeah, Florida, United States

Galderma Investigational Site 8706; 🇺🇸 Miami, Florida, United States

Galderma Investigational Site 8729; 🇺🇸 Rolling Meadows, Illinois, United States

Galderma Investigational Site 8724; 🇺🇸 New Albany, Indiana, United States

Galderma Investigational Site 8554; 🇺🇸 Detroit, Michigan, United States

Galderma Investigational Site 8506; 🇺🇸 Hackensack, New Jersey, United States

Galderma Investigational Site 8030; 🇺🇸 Raleigh, North Carolina, United States

Galderma Investigational Site 8723; 🇺🇸 Cortland, New York, United States

Galderma Investigational Site 8741; 🇺🇸 Buffalo, New York, United States

Galderma Investigational Site 8733; 🇺🇸 New York, New York, United States

Galderma Investigational Site 8713; 🇺🇸 North Charleston, South Carolina, United States

Galderma Investigational Site 8003; 🇺🇸 Webster, Texas, United States

Galderma Investigational Site 6078; 🇧🇬 Sofia, Bulgaria

Galderma Investigational Site 8434; 🇺🇸 Seattle, Washington, United States

Galderma Investigational Site 6080; 🇧🇬 Sofia, Bulgaria

Galderma Investigational Site 6069; 🇪🇪 Tallinn, Estonia

Galderma Investigational Site 6167; 🇫🇷 Nantes, France

Galderma Investigational Site 6198; 🇫🇷 Le Mans, France

Galderma Investigational Site 5031; 🇫🇷 Lille, France

Galderma Investigational Site 6166; 🇫🇷 Paris, France

Galderma Investigational Site 5407; 🇫🇷 Pierre-Bénite, France

Galderma Investigational Site 6168; 🇫🇷 Valence, France

Galderma Investigational Site 6230; 🇬🇪 Tbilisi, Georgia

Galderma Investigation Site 6228; 🇬🇪 Tbilisi, Georgia

Galderma Investigational Site 5566; 🇩🇪 Augsburg, Germany

Galderma Investigational Site 6082; 🇩🇪 Bonn, Germany

Galderma Investigational Site 6235; 🇬🇪 Tbilisi, Georgia

Galderma Investigational Site 5482; 🇩🇪 Aachen, Germany

Galderma Investigational Site 6132; 🇩🇪 Dresden, Germany

Galderma Investigational Site 6083; 🇩🇪 Frankfurt, Germany

Galderma Investigational Site 6081; 🇩🇪 Goettigen, Germany

Galderma Investigational Site 6041; 🇩🇪 Hamburg, Germany

Galderma Investigational Site 6150; 🇩🇪 Hamburg, Germany

Galderma Investigational Site 5469; 🇩🇪 Heidelberg, Germany

Galderma Investigational Site 5513; 🇭🇺 Budapest, Hungary

Galderma Investigational Site 6147; 🇭🇺 Budapest, Hungary

Galderma Investigational Site 5382; 🇩🇪 Munich, Germany

Galderma Investigational Site 5567; 🇭🇺 Debrecen, Hungary

Galderma Investigational Site 6145; 🇮🇹 Bologna, Italy

Galderma Investigational Site 6143; 🇮🇹 Pisa, Italy

Galderma Investigational Site 5377; 🇵🇱 Nowa Sól, Poland

Galderma Investigational Site 6175; 🇮🇹 Vicenza, Italy

Galderma Investigational Site 6155; 🇮🇹 Rozzano, Italy

Galderma Investigational Site 6085; 🇵🇱 Poznań, Poland

Galderma Investigational Site 6048; 🇵🇱 Tarnów, Poland

Galderma Investigational Site 6126; 🇵🇱 Warsaw, Poland

Galderma Investigational Site 6124; 🇸🇬 Singapore, Singapore

Galderma Investigational Site 5707; 🇵🇱 Warsaw, Poland

Galderma Investigational Site 6077; 🇸🇬 Singapore, Singapore

Galderma Investigational Site 5499; 🇸🇬 Singapore, Singapore

Galderma Investigational Site 6062; 🇩🇪 Halle, Germany

Galderma Investigational Site 6102; 🇧🇬 Sofia, Bulgaria

Galderma Investigational Site 6079; 🇧🇬 Sofia, Bulgaria

Galderma Investigational Site 6029; 🇧🇬 Pleven, Bulgaria

Galderma Investigational Site 6216; 🇧🇬 Sofia, Bulgaria

Galderma Investigational Site 6046; 🇧🇬 Sofia, Bulgaria

Galderma Investigational Site 6067; 🇪🇪 Tartu, Estonia

Galderma Investigational Site 6234; 🇬🇪 Tbilisi, Georgia

Galderma Investigational Site 6097; 🇵🇱 Chorzów, Poland

Galderma Investigational Site 5362; 🇵🇱 Cracovia, Poland

Galderma Investigational Site 6063; 🇵🇱 Olsztyn, Poland

Galderma Investigational Site 6068; 🇪🇪 Tallin, Estonia

Galderma Investigational Site 6236; 🇬🇪 Zugdidi, Georgia

Galderma Investigational Site 6053; 🇭🇺 Veszprém, Hungary

Galderma Investigational Site 5021; 🇵🇱 Katowice, Poland

Galderma Investigational Site 5495; 🇵🇱 Rzeszów, Poland

Galderma Investigational Site 6096; 🇵🇱 Wrocław, Poland

Galderma Investigational Site 6051; 🇧🇬 Sofia, Bulgaria

Galderma Investigational Site 6238; 🇬🇪 Tbilisi, Georgia

Galderma Investigational Site 5367; 🇵🇱 Lublin, Poland

Galderma Investigational Site 6251; 🇧🇬 Stara Zagora, Bulgaria

Galderma Investigational Site 6026; 🇭🇺 Debrecen, Hungary

Galderma Investigational Site 6130; 🇵🇱 Szczecin, Poland

Galderma Investigational Site 8896; 🇺🇸 Richmond, Virginia, United States